Latest Oncology News

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

December 23rd 2024

Kyle Doherty

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

Courtney Flaherty

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

December 23rd 2024

Megan Hollasch

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

December 23rd 2024

Philippe Moreau, MD

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Ashling Wahner

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Latest Oncology Videos

Introduction and Incidence of HPV-Positive Head and Neck Cancer
Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease
Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma
Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Deep and Sustained Responses in Patients With CLL Treated With Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report From the Zanubrutinib Extension Study
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
Understanding Graft-VS-Host Disease (GVHD) Basics
Initial Treatment Strategies for Polycythemia Vera
Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL
Insights on the LANCE Pilot Study on Lung LCNEC
The Role of DLL3 in LCNEC of the Lung
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL
Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma
Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression
Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer
Dr Watson on the Use of Oncogene Analysis to Determine Clinically Relevant HER2, KRAS and MET Copy-Number Gain in NSCLC
Treatment Trends: JAK Inhibitor Selection in Myelofibrosis
DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma
Treatment Strategies for Relapsed/Refractory AML Patients
Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

All Oncology News

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

December 23rd 2024

Chris Ryan

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

December 23rd 2024

Chris Ryan

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

UC Davis Researchers Help Decode the Cause of Aggressive Breast Cancer in Women of Color

December 23rd 2024

UC Davis Comprehensive Cancer Center

Findings point to a biomarker that may give a “head start” to triple-negative breast cancer in Black women.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

December 23rd 2024

Kristi Rosa

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

December 23rd 2024

Courtney Flaherty

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC

December 22nd 2024

Ryan Scott

Aparna Parikh, MD, discussed novel agents that are currently at play in the mutated, metastatic colorectal cancer treatment field.

The OncFive: Top Oncology Articles for the Week of 12/15

December 21st 2024

OncLive Staff

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

December 21st 2024

Gina Mauro

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

December 20th 2024

Chris Ryan

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

December 20th 2024

Courtney Flaherty

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

December 20th 2024

Chris Ryan

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

December 20th 2024

Megan Hollasch

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

December 20th 2024

Ryan Scott

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.

Uproleselan Plus Chemo Fails to Improve OS in R/R AML in China

December 20th 2024

Chris Ryan

Uproleselan plus chemotherapy did not improved overall survival in relapsed/refractory acute myeloid leukemia.

Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm

December 20th 2024

Ryan Scott

John Mascarenhas, MD, discusses navtemadlin's mechanism of action and its potential to shift the myelofibrosis treatment landscape

See All News